Amsacrine
Topoisomerase Inhibitor
DB00276
Approved Indication
For treatment of acute myeloid leukaemia.
4
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Amsacrine binds to DNA through intercalation and external binding. It has a base specificity for A-T pairs. Rapidly dividing cells are two to four times more sensitive to amsacrine than are resting cells. Amsacrine appears to cleave DNA by inducing double stranded breaks. Amsacrine also targets and inhibits topoisomerase II. Cytotoxicity is greatest during the S phase of the cell cycle when topoisomerase levels are at a maximum.
Details
DrugBank ID
DB00276 ↗
Approval Date
—
Molecular Weight
393.459 g/mol
Drug Class
Topoisomerase Inhibitor
ATC Codes
L01XX01
Synonyms
Acridinyl anisidide, Amsacrine, m-AMSA
PubChem
CID: 2179 ↗
ChEMBL
CHEMBL43 ↗
SMILES
COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1
ADMET Profile
Computing properties…